S. Ikeda

发表

Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice.

Motohiro Kato, Y. Aso, M. Ishigai, 2012, Journal of pharmaceutical sciences.

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus

S. Iida, Tomohisa Saito, D. Schwab, 2018, Drug Research.

Oxidized low density lipoprotein caused CNS neuron cell death

M. Sugawa, O. Cynshi, Y. Kushima, 1997, Brain Research.

Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

T. Fukuzawa, Takamitsu Kobayashi, Y. Kawabe, 2012, Journal of Pharmacology and Experimental Therapeutics.

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

Motohiro Kato, Y. Kawabe, Kiyofumi Honda, 2013, American journal of physiology. Endocrinology and metabolism.

Microsoft Word-22160437-file00.docx

Takamitsu Kobayashi, Masayuki Suzuki, S. Ikeda, 2012 .

In vitro profiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

C. Funk, A. Poirier, Y. Aso, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects

T. Ichihara, Y. Kumagai, H. Fukase, 2017, Drug Research.

5a-Carba-β-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

Motohiro Kato, M. Ohmori, N. Shimma, 2011, Bioorganic & medicinal chemistry.

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

M. Ohmori, Takamitsu Kobayashi, Tsutomu Sato, 2012, Journal of medicinal chemistry.

Pharmacokinetic and Pharmacodynamic Modeling of the Effect of an Sodium-Glucose Cotransporter Inhibitor, Phlorizin, on Renal Glucose Transport in Rats

Y. Aso, M. Ishigai, K. Yamaguchi, 2011, Drug Metabolism and Disposition.

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.

T. Kadowaki, N. Kubota, Yoshitaka Sakurai, 2016, Endocrinology.

A Pharmacokinetic/Pharmacodynamic Drug–Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs

H. Fukase, M. Harigai, S. Iida, 2015, Drug Research.

C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

M. Ohmori, N. Shimma, Takamitsu Kobayashi, 2012, Bioorganic & medicinal chemistry.

In Vitro–In Vivo Correlation of the Inhibition Potency of Sodium-Glucose Cotransporter Inhibitors in Rat: A Pharmacokinetic and Pharmacodynamic Modeling Approach

Y. Aso, M. Ishigai, K. Yamaguchi, 2013, The Journal of Pharmacology and Experimental Therapeutics.

A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

T. Kadowaki, M. Meyer, T Kadowaki, 2015, Diabetes, obesity & metabolism.

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

Y. Kawabe, Kiyofumi Honda, Mio Kawai, 2013, American journal of physiology. Endocrinology and metabolism.